In collaboration with

Title: Exploring Chronic Spontaneous Urticaria

Release | Expiration: September 8, 2025 – September 8, 2026

Statement of Need:

Chronic spontaneous urticaria (CSU) is a burdensome inflammatory skin disease that significantly impairs quality of life and remains challenging to manage despite the availability of evidence-based guidelines and effective therapies. Many clinicians lack familiarity with streamlined diagnostic approaches, often resorting to unnecessary and costly testing that delays appropriate treatment. In addition, limited understanding of CSU endotypes, biomarkers, and their implications for individualized therapy hinders the ability to optimize treatment decisions. These gaps contribute to delayed diagnoses, inappropriate prescribing, and trial-and-error treatment strategies that prolong patient suffering.

Furthermore, adherence to recommended treatment algorithms is inconsistent, with persistent reliance on first-generation antihistamines and systemic corticosteroids, despite their risks and limited efficacy. As the therapeutic landscape rapidly evolves with novel biologics and targeted therapies, many clinicians remain unaware of emerging agents, their mechanisms of action, and appropriate patient selection criteria. This lack of awareness delays access to effective treatments for patients with difficult-to-treat CSU. Targeted continuing medical education is urgently needed to equip clinicians with the knowledge and skills to implement guideline-based diagnostic and treatment strategies, integrate biomarkers into clinical decision-making, and apply emerging therapies effectively to improve patient outcomes.
 

Educational Objectives:

1. APPLY evidence-based diagnostic guidelines, including appropriate use of laboratory tests and imaging, to optimize the diagnostic workup for patients with CSU
2. INTEGRATE knowledge of CSU endotypes and validated and emerging biomarkers, including total serum IgE levels, to individualize treatment strategies and predict response to targeted therapies
3. IMPLEMENT current, evidence-based treatment algorithms for CSU, including appropriate prescribing and dosing of antihistamines, omalizumab, and other therapies, while avoiding inappropriate or unnecessary use of first-generation antihistamines and/or long-term OCS
4. EVALUATE the efficacy and safety data for novel therapies for CSU to determine the appropriate use and place in therapy for patients with CSU

Target Audience: Community-Based Dermatologists, Pediatric Dermatologists, Allergists and APPs within these specialty practices

Faculty:

David M. Lang, MD
Emeritus Staff, Department of Allergy & Clinical Immunology, Cleveland Clinic
Professor of Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University
Cleveland, OH

Relevant Relationships: AstraZeneca (Consultant); Bluepoint (Advisory Board); Celidex (Consultant); Genentech (Advisory Board); Novartis (Advisory Board); Novartis (Consultant); Sanofi-Regeneron (Speaker)

 

Allen P. Kaplan, MD
Clinical Professor of Medicine, Medical University of South Carolina (MUSC)
Charleston, SC

Relevant Relationships: None

Technical Writer:

Erika L Kunz, PharmD

Disclosures:

Accredited Provider Disclosure:
None of the planners, reviewers, and AAAAI / GatherEd staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.

Disclosure of Financial Relationships Policy:
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accredited Provider & Accreditation Statements:
This activity is accredited through AAAAI.

CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.

Credit Designation Statement:
The AAAAI designates this activity for up to 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credits:

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. 

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 7.25 hours of Category 1 credit for completing this program.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use:
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI, RealCME, or GatherEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org

Method of Participation/Instructions:
Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Core Curriculum: Three (3) Self-Study Modules: 15 minutes each for a total of up to .75 hour of CME
• Updates: Four (4) Post-meeting Self Study Update Modules: 15 minutes each for a total of up to 1.00 hour of CME
• Four (4) Live Group Discussions: 45 minutes each for a total of up to 3.00 hour of CME
• Four Group Challenges (4): 15 minutes each for a total of up to 1.00 hour of CME
• Action Plan (1) development: 30 minutes for a total of up to 0.50 hour of CME

Privacy Statement:

AAAAI Privacy and Data Protection Policy for CME Programs

The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this event ("the Course"), to provide services that you have requested from AAAAI, and otherwise as you may expressly consent.

By providing consent, you are allowing AAAAI and our educational partners involved in this Course to process your personal data. AAAAI will collect and store information you provide in the Registration Form for the purposes of enabling us to register your attendance in this Course, to assist with administrative, planning, and marketing purposes, and to allow the compilation and analysis of statistics relevant to AAAAI and our educational partners.

The information you provide in the Registration Form and information provided at any other time during the Course, including without limitation any feedback obtained during the Course, will be used by AAAAI to offer, provide, and continue to improve this Course and other services. With your permission, AAAAI may disclose some information collected in the Registration Form, such as your name, organization, address, telephone and fax numbers, and email address to industry supporters (subject to conditions) for marketing purposes. AAAAI will also use your email address to communicate important information regarding this event and for marketing purposes for future events.

AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision, and improvement of the Course or where such purpose is permitted or required by law.

AAAAI emphasizes that industry supporters of the Course may request that you share your contact information for the purpose of participating in a sponsored event outside of the Course agenda. This data transaction is considered a direct transfer of your information to the industry supporter. AAAAI does not control the usage of information transferred this way and, as such, AAAAI shall not be held responsible for any misuse of your personal data retrieved by industry supporters. You have the option to decline an industry supporter’s request to share your contact information and can ask them questions about how they will use your personal data, how long it will be retained, and if they will share information with third parties.

Commercial Supporters: Sanofi and Regeneron